Optimizing Cell Therapy Supply Chains For Success: Why Outsourcing Expertise Is Critical

Source: Catalent

The use of cell therapies—particularly autologous therapies where human cells are collected, reprogrammed, and then readministered to the same patient—has grown rapidly over the years and is experiencing increased demand across the industry. While these advanced medicines are enabling treatment for serious and even  life-threatening diseases, they require specific packaging and distribution strategies to ensure high product quality and patient safety.

When it comes to transporting these highly sensitive and valuable materials, ensuring that their unique storage and distribution requirements are met is critical. A CDMO who specializes in cell and gene therapies and can cover end-to-end development and supply can be a beneficial partner to sponsors of these therapies.

access the E-Book!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online